Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Common Equity (2019 - 2025)

AVITA Medical (RCEL) has disclosed Common Equity for 6 consecutive years, with -$16.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 470.08% year-over-year to -$16.6 million, compared with a TTM value of -$16.6 million through Dec 2025, down 470.08%, and an annual FY2025 reading of -$16.6 million, down 470.08% over the prior year.
  • Common Equity was -$16.6 million for Q4 2025 at AVITA Medical, down from -$6.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $97.8 million in Q1 2022 and bottomed at -$16.6 million in Q4 2025.
  • Average Common Equity over 4 years is $40.9 million, with a median of $40.8 million recorded in 2023.
  • The sharpest move saw Common Equity dropped 20.71% in 2023, then tumbled 470.08% in 2025.
  • Year by year, Common Equity stood at $84.7 million in 2022, then tumbled by 42.11% to $49.1 million in 2023, then plummeted by 90.83% to $4.5 million in 2024, then crashed by 470.08% to -$16.6 million in 2025.
  • Business Quant data shows Common Equity for RCEL at -$16.6 million in Q4 2025, -$6.7 million in Q3 2025, and -$12.9 million in Q2 2025.